Thus, our data suggest that inhibition of CDK8/19 by our compounds contributes to anti-proliferative activity in prostate cancer cells both in vitro and in vivo, although it remains possible that the effects may be influenced by the inhibition of a protein other than CDK8/19. The gene discussed is CDK8; the disease is prostate carcinoma.